https://doi.org/10.4081/btvb.2022.38
Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy
Submitted: 9 May 2022
Accepted: 4 July 2022
Published: 21 July 2022
Accepted: 4 July 2022
Abstract Views: 2807
PDF: 278
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Not available
Nangalia J, Mitchell E, Green AR. Clonal approaches to understanding the impact of mutations on hematologic disease development. Blood 2019;133:1436-45.
DOI: https://doi.org/10.1182/blood-2018-11-835405
Lee J, Godfrey AL, Nangalia J. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Blood Rev 2020;42:100708.
DOI: https://doi.org/10.1016/j.blre.2020.100708
Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica 2017;102:7-17.
DOI: https://doi.org/10.3324/haematol.2014.113845
Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 2022;6:e12657.
DOI: https://doi.org/10.1002/rth2.12657
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021;35:3339-51.
DOI: https://doi.org/10.1038/s41375-021-01401-3
Hultcrantz, M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 2018;168:317-25.
DOI: https://doi.org/10.7326/M17-0028
Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-98.
DOI: https://doi.org/10.1056/NEJMoa1408617
Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477-87.
DOI: https://doi.org/10.1056/NEJMoa1409405
Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:1472-8.
DOI: https://doi.org/10.1038/nm.3733
Khetarpal SA, Qamar A, Bick AG, et al. Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74:578-86.
DOI: https://doi.org/10.1016/j.jacc.2019.05.045
Busque L, Sun M, Buscarlet M, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv 2020;4:2430-8.
DOI: https://doi.org/10.1182/bloodadvances.2019000770
Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment containing TNFa favors Tet2-mutant clonal hematopoiesis. Exp Hematol 2018;59:60-65.
DOI: https://doi.org/10.1016/j.exphem.2017.11.002
Bjørn ME, Hasselbalch HC. The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators Inflamm 2015;2015:648090.
DOI: https://doi.org/10.1155/2015/648090
Vener C, Novembrino FB, Bamonti Catena F, et al. Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. Exp Hematol 2010;38:1058-65.
DOI: https://doi.org/10.1016/j.exphem.2010.07.005
Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression. Leukemia 2013;27:2187-95.
DOI: https://doi.org/10.1038/leu.2013.102
Menendez-Gonzalez JB, Rodrigues NP. Exploring the associations between clonal hematopoiesis of indeterminate potential, myeloid malignancy, and atherosclerosis. Methods Mol Biol 2022;2419:73-88.
DOI: https://doi.org/10.1007/978-1-0716-1924-7_5
Baumeister J, Chatain N, Sofias AM, et al. Progression of Myeloproliferative Neoplasms (MPN): diagnostic and therapeutic perspectives. Cells 2021;10:3551.
DOI: https://doi.org/10.3390/cells10123551
Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119:3219-25.
DOI: https://doi.org/10.1182/blood-2011-11-394775
Fleischman AG, Aichberger KJ, Luty SB, et al. TNFα Facilitates Clonal Expansion of JAK2V617F Positive Cells in Myeloproliferative Neoplasms. Blood 2011;118:6392-8.
DOI: https://doi.org/10.1182/blood-2011-04-348144
Tefferi A, Vaidya R, Caramazza D, et al. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356–1363.
DOI: https://doi.org/10.1200/JCO.2010.32.9490
Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science 2019;366:eaan4673.
DOI: https://doi.org/10.1126/science.aan4673
Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity 2022;55:31-55.
DOI: https://doi.org/10.1016/j.immuni.2021.12.013
Leiva O, Hobbs G, Ravid K, Libby P. Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review. J Am Coll Cardiol Cardio Onc 2022;4:166-82.
DOI: https://doi.org/10.1016/j.jaccao.2022.04.002
Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011;96:315-8.
DOI: https://doi.org/10.3324/haematol.2010.031070
Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-3.
DOI: https://doi.org/10.1182/blood-2006-09-046342
Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732-6.
DOI: https://doi.org/10.1200/JCO.2007.15.3569
Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019;3:1729-37.
DOI: https://doi.org/10.1182/bloodadvances.2019000211
Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-52.
DOI: https://doi.org/10.1182/blood-2006-08-042515
Ronner L, Podoltsev N, Gotlib J, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood 2020;135:1696-703.
DOI: https://doi.org/10.1182/blood.2019003347
Cordua S, Kjaer L, Skov V, et al. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood 2019;134:469-79.
DOI: https://doi.org/10.1182/blood.2019001113
Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood 2021;137:1517-26.
DOI: https://doi.org/10.1182/blood.2020005407
van Os B, Lutgens E. SPARCing the clot. Blood 2021;137:1441-2.
DOI: https://doi.org/10.1182/blood.2020009204
Carobbio A, Vannucchi AM, De Stefano V, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J 2022;12:28.
DOI: https://doi.org/10.1038/s41408-022-00625-5
Guglielmelli P, Loscocco GG, Mannarelli C, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J 2021;11:199.
DOI: https://doi.org/10.1038/s41408-021-00581-6
Farrukh F, Guglielmelli P, Loscocco GG, et al. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. Am J Hematol 2022;97:E35-7.
DOI: https://doi.org/10.1002/ajh.26423
How to Cite
Barbui, T. (2022). Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy. Bleeding, Thrombosis and Vascular Biology, 1(2). https://doi.org/10.4081/btvb.2022.38
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Vincenzo Sammartano, Adele Santoni, Elisabetta Zappone, Paola Calzoni, Daniela Fineschi, Eleonora Franceschini, Federico Caroni, Anna Sicuranza, Monica Bocchia, Luca Puccetti, A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Sergio Coccheri, A re-appraisal of thrombogenesis in COVID-19, seen as a multiple "Complex system" , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Robert Parambi, Nicole Ziliotto, Francesco Bernardi , Marcello Baroni , Richard W Browne , Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov, Murali Ramanathan, Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Daniela Tormene, Elena Campello, Chiara Simion, Anna Poretto, Paolo Prandoni, Paolo Simioni, Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Jingnan Huang, Delia I. Fernández, Jinmi Zou, Xueqing Wang, Johan W.M. Heemskerk, Ángel García, Restrained glycoprotein VI-induced platelet signaling by tyrosine protein phosphatases independent of phospholipase Cγ2 , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Mattia Galli, C. Michael Gibson, Dominick J. Angiolillo, Factor XI inhibitors in adjunct to antiplatelet therapy: the ultimate dual-pathway inhibition? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Pier Mannuccio Mannucci, Growing weapons to fight hemophilia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Pier Mannuccio Mannucci, Gene transfer in hemophilia A: not cogent yet , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Kristen M. Sanfilippo, Tzu-Fei Wang, Venous thromboembolism and mortality in patients with hematological malignancies , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Roberta Parisi, Simona Costanzo, Romy de Laat-Kremers, Augusto Di Castelnuovo, Amalia De Curtis, Teresa Panzera, Mariarosaria Persichillo, Chiara Cerletti, Giovanni de Gaetano, Maria Benedetta Donati, Licia Iacoviello, Bas de Laat , for the Moli-sani Study Investigators, Plasma fibrinogen levels and all-cause and cause-specific mortality in an Italian adult population: results from the Moli-sani study , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
You may also start an advanced similarity search for this article.
